| Name | Title | Contact Details |
|---|---|---|
Amanda O?Malley |
Human Resources Director | Profile |
Krista Davis |
Senior Vice President and Chief Human Resources Officer | Profile |
Sherri Bitter |
Vice President, Human Resources | Profile |
Loretta Bright |
Senior Human Resource Professional | Profile |
Arthur Przybyl |
President and Chief Executive Officer | Profile |
Navicent Health was incorporated on November 17, 1994, as a nonprofit corporation whose primary purpose is to coordinate the Medical Center, Navicent Health and other affiliated entities in their mission of providing a comprehensive continuum of high quality, reasonably priced healthcare services to the region. Navicent Health has 830 beds for medical, surgical, rehabilitation and hospice purposes. The Medical Center, Navicent Health – a nationally recognized tertiary teaching hospital and the primary teaching hospital for Mercer University School of Medicine - includes but is not limited to: •Peyton Anderson Cancer Center, Navicent Health, a provider of comprehensive cancer care. Our services cover the continuum of cancer care, from screening and diagnosis through treatment and into survivorship. •Emergency Center, Navicent Health provides access to our Level 1 Trauma Center and includes helipad capability. The Emergency Center, along with our three urgent care locations, treat over 120,000 visitors per year. •Family Birth Center, Navicent Health has spacious labor and delivery suites, focuses on providing a family-friendly and family-centered environment for expectant mothers and their babies, and specializes in care for difficult pregnancies. •Heart Center, Navicent Health provides a full range of services for the prevention, diagnosis and treatment of cardiovascular disease, including congestive heart failure. •Rehabilitation Hospital, Navicent Health is the oldest and most experienced medical rehabilitation provider in central Georgia providing comprehensive services to help patients achieve their highest level of mobility and independence. •Beverly Knight Olson Children`s Hospital, Navicent Health, the region`s only dedicated pediatric hospital Navicent Health is the region`s leading provider of a comprehensive continuum of services. Whatever your healthcare needs, Navicent Health is here to assist you and your loved ones.
Medical Center Compounding is a Cleveland, TN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
A discovery through early clinical phase pharmaceutical company, Ratio Therapeutics employs a suite of innovative technologies to develop best-in-class targeted radiotherapeutics for the treatment of cancer. Ratio Therapeutics` Trillium™ targeting scaffold combines pharmacokinetic modulation with best-in-class chelation technology to create proprietary small molecule targeting agents to attack a broad array of cancer targets. Our compounds accommodate imaging and therapeutic radioisotopes, ie "theranostics". The tunable nature of our platform combined with small-scale imaging trials in patients results in accelerated, de-risked compound selection.
Aurobindo Pharma Limited is a pharmaceutical manufacturing company headquartered in HITEC City, Hyderabad, India.
Corcept Therapeutics Incorporated, a pharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of metabolic, oncologic, and psychiatric disorders in the United States. The company focuses on disorders that are associated with a steroid hormone called cortisol. It offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. The company is also developing Korlym’s active ingredient, which is in a Phase 1/2 trial in combination with the chemotherapy drug eribulin (Halaven) to treat patients with GR-positive triple-negative breast cancer, a form of cancer with a particularly poor prognosis; and CORT 125134, a proprietary, selective GR antagonist that is in a Phase 1 clinical study to assess its safety, tolerability, and pharmacokinetics in healthy human volunteers. In addition, it discovers and develops three series of novel selective GR-II antagonists. The company has research and development agreements with Argenta Discovery Limited and Sygnature Discovery Limited. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California.